




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07D 401/04, C07F 7/08, A61K 31/44, 31/695, C07D 401/14, 451/02, 403/04, A61K 31/445</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/01449</b> <b>(43) International Publication Date:</b> 14 January 1999 (14.01.99)
<b>(21) International Application Number:</b> PCT/EP98/03930 <b>(22) International Filing Date:</b> 26 June 1998 (26.06.98)  <b>(30) Priority Data:</b> 9713726.9                      30 June 1997 (30.06.97)                      GB  <b>(71) Applicant (for all designated States except AT US):</b> NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH).  <b>(71) Applicant (for AT only):</b> NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A-1235 Vienna (AT).  <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> RÉVÉSZ, László [CH/CH]; Ob dem Fichtenrain 7, CH-4106 Therwil (CH).  <b>(74) Agent:</b> BECKER, Konrad; Novartis AG, Patent- und Markenabteilung, Lichtstrasse 35, CH-4002 Basel (CH).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> 2-SUBSTITUTED 4,5-DIARYL IMIDAZOLES  <div style="text-align: center;">          (I)     </div> <b>(57) Abstract</b> <p>Novel 2-substituted 4,5-diaryl imidazoles in which: i) the nitrogen atom at the 1 position is substituted by a trialkylsilyl-containing substituent, or ii) the substituent at the 2 position is arylalkyl, arylsulfonyl, arylthio arylseleno, aryltelluro, cycloalkyl, cycloalkenyl, alkylcycloalkyl, alkylcycloalkenyl, amino or hydrazino, or mono- or bicyclic N-heterocyclyl in which the N containing ring has six ring members, are provided, in particular compounds of Formula (I) wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> are as defined, in free or pharmaceutically-acceptable acid addition salt or physiologically-cleavable ester form, which have p38 MAP kinase (Mitogen Activated Protein Kinase) inhibiting activity. The compounds are used as pharmaceuticals for treating TNFα and IL-1 mediated diseases such as rheumatoid arthritis and diseases of bone metabolism, e.g. osteoporosis.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CJ	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

### 2-Substituted 4,5-diaryl imidazoles

This invention relates to 2-substituted 4,5-diaryl imidazoles and to their use for treating TNF $\alpha$  and IL-1 mediated diseases such as rheumatoid arthritis and diseases of bone metabolism, e.g. osteoporosis.

Accordingly the present invention provides novel 2-substituted 4,5-diaryl imidazoles in which:

- i) the nitrogen atom at the 1 position is substituted by a trialkylsilyl-containing substituent, or
- ii) the substituent at the 2 position is arylalkyl, arylsulfonyl, arylthio arylseleno, aryltelluro, cycloalkyl, cycloalkenyl, alkylcycloalkyl, alkylcycloalkenyl, amino or hydrazino, or mono- or bicyclic N-heterocyclyl in which the N containing ring has six ring members, provided that the substituent at the 2 position is not piperidin-4-yl, 1-carboxylic-acid-tert-butyl-ester-4-benzyl-piperidin-4-yl, 1,4-dimethyl-piperidin-4-yl, 4-benzyl-piperidin-4-yl, or piperidin-4-yl which is further substituted only at the N atom

and pharmaceutically-acceptable acid addition salts thereof and physiologically-cleavable esters thereof.

The 4- or 5-aryl substituent may be any of those known in the art; for instance, as described in WO 95/03297 and WO 97/12876. For example, the 4- and 5-aryl substituents may be as hereinafter defined for R<sub>1</sub> and R<sub>2</sub> of formula I and include heteroaryl substituents.

When the nitrogen atom at the 1 position is substituted by a trialkylsilyl-containing substituent, the substituent is suitably a trialkylsilylalkoxyalkyl substituent.


When the substituent at the 2 position is arylalkyl, it is conveniently phenylalkyl.

When the substituent at the 2 position is arylalkyl, arylsulfonyl, arylthio arylseleno, aryltelluro, cycloalkyl, cycloalkenyl, alkylcycloalkyl, alkylcycloalkenyl,

amino or hydrazino, or mono- or bicyclic N-heterocyclyl, it may be further substituted, e.g. by up to 6 substituents selected from halo, OH, C<sub>1-4</sub>alkyl, C<sub>2-4</sub>alkenyl, C<sub>2-4</sub>alkynyl, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub> thioalkoxy, nitro, amino, C<sub>1-4</sub>alkylsulphinyl, C<sub>1-4</sub> alkylsulphonyl, carboxylate or ester.

Above and elsewhere in the present description the terms halo or halogen denote I, Br, Cl or F, preferably F.

In particular embodiments the invention provides a compound of formula I



wherein

R<sub>1</sub> is 4-pyridyl, pyrimidinyl, quinazolin-4-yl, quinolyl, isoquinolyl, 1-imidazolyl or 1-benzamidazolyl, which is optionally substituted with one or two substituents each of which is independently selected from

C<sub>1-4</sub>alkyl, halogen, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkylthio, NR<sub>5</sub>R<sub>6</sub>, or an N-heterocyclyl ring having 5 to 7 ring atoms and optionally containing an additional heteroatom selected from O, S, or N

wherein R<sub>5</sub> and R<sub>6</sub> is each independently C<sub>1-4</sub>alkyl;

R<sub>2</sub> is phenyl, naphth-1-yl or naphth-2-yl which is optionally substituted by up to 5 substituents;

R<sub>3</sub> is hydrogen,

heterocyclyl,

heterocyclylC<sub>1-10</sub>alkyl,

triC<sub>1-4</sub>alkylsilylC<sub>1-10</sub>alkoxyC<sub>1-4</sub>alkyl,

optionally halo substituted C<sub>1-10</sub>alkyl, C<sub>2-10</sub> alkenyl, C<sub>2-10</sub> alkynyl, C<sub>3-7</sub> cycloalkyl, C<sub>3-7</sub> cycloalkylC<sub>1-10</sub>alkyl, C<sub>5-7</sub> cycloalkenyl, aryl, arylC<sub>1-10</sub>alkyl, heteroaryl, or heteroarylC<sub>1-10</sub>alkyl,

optionally mono-or di- $C_{1-4}$ alkyl-substituted  $C_{0-10}$ alkyl-oxycarbonyl or -oxythiocarbonyl optionally substituted by  $C_{1-10}$ alkyl,  $C_{3-7}$  cycloalkyl, heterocyclyl, heterocyclyl $C_{1-10}$ alkyl, aryl, aryl $C_{1-10}$ alkyl, heteroaryl, heteroaryl $C_{1-10}$ alkyl, or

optionally mono-or di- $C_{1-4}$ alkyl-substituted  $C_{1-10}$ alkyl

-cyano,

-nitro,

-hydroxy,  $-C_{1-10}$ alkoxy,  $-C_{3-7}$ cycloalkoxy, -heterocycloxy, -heterocyclyl $C_{1-10}$ alkoxy, -aryloxy, -aryl $C_{1-10}$ alkoxy, -heteroaryloxy, -heteroaryl $C_{1-10}$ alkoxy (and thio oxy analogues thereof),

optionally substituted amino, carboxylate, thiocarboxylate, carbonyl or thiocarbonyl, sulphinyl or sulphonyl;

$R_4$  is  $-C_{0-4}$ alkyl mono-or di- $C_{3-7}$ cycloalkyl optionally substituted by -halo, -OH,  $-C_{1-4}$ alkyl,  $-C_{1-4}$ alkoxy,  $-C_{1-4}$ thioalkoxy, -nitro, -amino,  $-C_{1-4}$ alkylsulphinyl,  $-C_{1-4}$ alkylsulphonyl, -carboxylate or -ester,  $-NR_7R_8$ ,  $NHNHR_9$ ,

wherein independently each  $R_7$ ,  $R_8$  or  $R_9$  is  $C_{1-4}$ alkyl,  $C_{2-4}$ alkenyl,  $C_{2-6}$ alkynyl,

-X-  $C_{5-10}$  aryl (including heteroaryl)

wherein X is S,  $SO_2$ , Se, Te or  $C_{1-4}$ alkyl,

mono-or bicyclic N-heterocyclyl in which the N containing ring has six ring members,

or aryl or heteroaryl optionally substituted by up to 4 substituents,

provided that

when  $R_3$  is not tri $C_{1-4}$ alkylsilyl $C_{1-10}$ alkoxy $C_{1-4}$ alkyl,

$R_4$  is not aryl or heteroaryl optionally substituted by up to 3 substituents, except when  $R_4$  is mono-or bicyclic N-heterocyclyl in which the N containing ring has six ring members, and

provided that

$R_4$  is not piperidin-4-yl, 1-carboxylic-acid-tert-butyl-ester-4-benzyl-piperidin-4-yl, 1,4-dimethyl-piperidin-4-yl, 4-benzyl-piperidin-4-yl, or piperidin-4-yl which is further substituted only at the N atom,

and pharmaceutically-acceptable acid addition salts thereof and physiologically-cleavable esters thereof.

$R_2$  is substituted by up to 5 substituents which may be any of the substituents known in the art; for instance, as described for  $R_4$  in WO 95/03297 and the substituent R of WO 97/12876.


When  $R_4$  is  $-X-C_{5-10}aryl$ , the  $C_{5-10}aryl$  or X, when it is  $C_{1-4}alkyl$ , may be substituted by up to 6 substituents selected from halo, OH,  $C_{1-4}alkyl$ ,  $C_{1-4}alkoxy$ ,  $C_{1-4}thioalkoxy$ , nitro, amino,  $C_{1-4}alkylsulphanyl$ ,  $C_{1-4}alkylsulphonyl$ , carboxylate or ester.

When  $R_4$  is mono-or bicyclic N-heterocyclyl in which the N containing ring has six ring members, it may be saturated or unsaturated, e.g. aromatic, heterocyclyl.

When  $R_4$  is aryl or heteroaryl optionally substituted by up to 4 substituents,  $R_4$  may comprise one of the customary aryl or heteroaryl substituents used in the art; for instance as defined for the substituent  $R_3$  of WO 93/03297.

Imidazoles with a 2-substituent, e.g.  $R_4$  as defined above, and with also aryl substituents at both positions 4 and 5, e.g. as defined for  $R_1$  and  $R_2$  above, in which the nitrogen atom at the 1 position is substituted by a trialkylsilyl-containing substituent are entirely novel.

Accordingly in a further aspect the invention provides a compound of formula I'



wherein

$R_3'$  is  $\text{triC}_{1-4}\text{alkylsilylC}_{1-10}\text{alkoxyC}_{1-4}\text{alkyl}$ , and  $R_1$ ,  $R_2$  and  $R_4$  are as defined above, and pharmaceutically-acceptable acid addition salts thereof and physiologically-cleavable esters thereof.

Compounds of formula I' in which  $R_4$  is H and  $R_2$ ,  $R_3'$  and  $R_4$  as defined above are key intermediates for the synthesis of other compounds of formula I in which  $R_3$  is not  $\text{triC}_{1-4}\text{alkylsilylC}_{1-10}\text{alkoxyC}_{1-4}\text{alkyl}$ , as hereinafter described.

The substituents  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_3'$  and  $R_4'$  independently have the following preferred significances.

Preferably  $R_1$  is 4-pyridyl or pyrimidinyl, especially 4-pyridyl.

$R_2$  is preferably phenyl, including substituted phenyl.


Most preferably  $R_3'$  is trimethylsilylethoxymethyl.

When  $R_3$  is  $\text{triC}_{1-4}\text{alkylsilylC}_{1-10}\text{alkoxyC}_{1-4}\text{alkyl}$ ,  $R_1$  is preferably 4-pyridyl.

When  $R_3$  is  $\text{triC}_{1-4}\text{alkylsilylC}_{1-10}\text{alkoxyC}_{1-4}\text{alkyl}$ ,  $R_2$  is preferably 4-fluorophenyl.

When  $R_3$  is  $\text{triC}_{1-4}\text{alkylsilylC}_{1-10}\text{alkoxyC}_{1-4}\text{alkyl}$ ,  $R_4$  is preferably H.


In a further preferred aspect of the invention  $R_4$  is  $-\text{X}-\text{C}_{5-10}\text{aryl}$ , preferably  $-\text{X}$ -phenyl, wherein X is as previously defined, e.g. a compound of formula III



III

wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $X$  are as defined above and  $R_{11}$  represent from 1-4, substituents independently selected from H, halo, OH,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy,  $C_{1-4}$  thioalkoxy, nitro, amino,  $C_{1-4}$  alkylsulphinyl,  $C_{1-4}$  alkylsulphonyl, carboxylate or ester, and pharmaceutically-acceptable acid addition salts thereof and physiologically-cleavable esters thereof.

In a yet further preferred aspect of the invention  $R_4$  is cycloalkyl, cycloalkenyl, alkylcycloalkyl, alkylcycloalkenyl, or mono- or bicyclic N-heterocyclyl in which the N containing ring has six ring members, e.g. a compound of formula IV



wherein  $R_1$ ,  $R_2$  and  $R_3$  are as defined above,  $D$  is  $C_{3-7}$ cycloalkyl,  $C_{3-7}$ cycloalkenyl or a mono- or bicyclic N-heterocyclyl in which the N containing ring has 6 ring members and  $X'$  is a direct bond or  $-CR_{12}R_{13}-$

wherein  $R_{12}$  is H or  $C_{1-4}$ alkyl and  $R_{13}$  is H or  $C_{1-4}$ alkyl optionally substituted by  $C_{3-7}$ cycloalkyl or  $C_{3-7}$ cycloalkenyl, and pharmaceutically-acceptable acid addition salts thereof and physiologically-cleavable esters thereof.

In formula IV  $X'$  and  $D$  may be further substituted, e.g. by up to 6 substituents selected from halo, OH,  $C_{1-4}$  alkyl,  $C_{1-6}$  alkoxy,  $C_{1-4}$  thioalkoxy, nitro, amino,  $C_{1-4}$  alkylsulphinyl,  $C_{1-4}$  alkylsulphonyl, carboxylate or ester.

Preferably  $D$  is cyclohexyl, cyclohexenyl, cyclopropyl, pyridinyl (e.g. 4-pyridinyl), piperidinyl (e.g. piperidin-4-yl), piperidenyl (e.g. piperiden-4-yl), azabicyclo[3,2,1]octanyl, azabicyclo[3,3,1]nonyl or tropanyl bicyclic N-heterocycles (and enyl analogues of such bicyclic N-heterocycles, e.g. 8-azabicyclo{3.2.1}oct-2-en-3-yl). In particularly preferred embodiments  $-X'-D$  is 1-hydroxycyclohexyl, 1-aminocyclohexyl, 1-cyclohexenyl, cyclopropylmethyl, 1,2-dicyclopropylethyl, 2,3,5,6-



tetrafluoropyridinyl, 2-amino-3,5,6-trifluoropyridinyl, 2,6-diamino-3,5-difluoropyridinyl, tropan-3-yl, 4-hydroxy-1-methylpiperidinyl, 4-C<sub>1-6</sub>alkoxy-1-methylpiperidinyl, e.g. 4-n-butyloxy-1-methylpiperidinyl, 8-methyl-8-azabicyclo{3.2.1}oct-2-en-3-yl, 1-methyl-4-piperidinyl.

When R<sub>4</sub> is -X-aryl or -X'-D, R<sub>1</sub> is preferably 4-pyridyl.

When R<sub>4</sub> is -X-aryl or -X'-D, R<sub>2</sub> is preferably halo substituted phenyl, especially 4-fluoro-phenyl.

When R<sub>4</sub> is -X-aryl or -X'-D, R<sub>3</sub> is preferably H.

Particularly preferred compounds of formula IV are those in which X' is a direct bond and D is optionally substituted pyridinyl, e.g. 4-pyridinyl, or piperidinyl, e.g. piperidin-4-yl.


The novel 2-substituted 4,5-diaryl imidazoles of the invention, in particular the compounds of formulae I to IV and the specific compounds of Examples 1-19 are hereinafter referred to as "Compounds of the Invention".

The Compounds of the Invention which comprise free hydroxyl groups may also exist in the form of pharmaceutically acceptable, physiologically cleavable esters, and as such are included within the scope of the invention. Such pharmaceutically acceptable esters are preferably prodrug ester derivatives, such being convertible by solvolysis or cleavage under physiological conditions to the corresponding Compounds of the Invention which comprise free hydroxyl groups. Suitable pharmaceutically acceptable prodrug esters are those derived from a carboxylic acid, a carbonic acid monoester or a carbamic acid, advantageously esters derived from an optionally substituted lower alkanolic acid or an arylcarboxylic acid.

The Compounds of the Invention may also exist in the form of pharmaceutically acceptable salts, and as such are included within the scope of the invention. Pharmaceutically acceptable salts include acid addition salts with

conventional acids, for example, mineral acids, e.g., hydrochloric acid, sulfuric or phosphoric acid, or organic acids, for example, aliphatic or aromatic carboxylic or sulfonic acids, e.g., acetic, propionic, succinic, glycolic, lactic, malic, tartaric, citric, ascorbic, maleic, fumaric, hydroxymaleic, pyruvic, pantoic, methanesulfonic, toluenesulfonic, naphthalenesulfonic, sulfanilic or cyclohexylsulfamic acid; also amino acids, such as arginine and lysine. For compounds of the invention having acidic groups, for example, a free carboxy group, pharmaceutically acceptable salts also represent metal or ammonium salts, such as alkali metal or alkaline earth metal salts, e.g., sodium, potassium, magnesium or calcium salts, as well as ammonium salts, which are formed with ammonia or suitable organic amines.


Compounds of the Invention of formulae III and IV as defined above may be prepared by reacting a compound of formula VIII



wherein  $R_1$  and  $R_2$  are as defined above, with the corresponding aldehyde, ketone, disulfonylamine, disulfide, diselenide, ditelluride or halide and, if required introducing the desired  $R_3$  substituent or further transforming the product obtained and optionally recovering it free or salt form. Thus for example, the compound of formula VIII is treated with the corresponding aldehyde, ketone, disulfonylamine, disulfide, diselenide, ditelluride or halide in the presence of  $n\text{-BuLi}$ , e.g. in cooled (e.g.  $-40^\circ\text{C}$ ) THF solution.


When the compound of formula VIII is treated with the corresponding aldehyde or ketone, the initial product obtained is 1-hydroxy substituted in the  $R_4$  substituent, e.g. 1-hydroxycyclohexyl when the ketone is cyclohexanone. The corresponding dehydrated compound, e.g.  $R_4$  is 1-cyclohexenyl, may be obtained, e.g. by treatment with  $p\text{TsOH}$  under reflux in toluene solution.

The invention includes a process for the preparation of a Compound of the Invention or salt of formulae III and IV as defined above which comprises reacting a compound of formula VIII



wherein  $R_1$  and  $R_2$  are as defined above,  
with the corresponding aldehyde, ketone, disulfonylamine, disulfide, diselenide, ditelluride or halide and, if required introducing the desired  $R_3$  substituent or further transforming the product obtained and optionally recovering the Compound of the Invention in free or salt form.

Compounds of formula VIII may be prepared by treating the corresponding 1H-imidazole of formula I, i.e. the corresponding compound of formula I in which  $R_4$  is H, with 2(trimethylsilyl)ethoxymethyl-halide (e.g. -chloride), e.g. in the presence of potassium bis-(trimethylsilyl)-amide in cooled (e.g.  $-78^\circ\text{C}$ ) DMF/THF solution. This procedure gives rise to a mixture of the corresponding 1-2(trimethylsilyl)-ethoxymethyl-imidazoles of formulae VIII and IX



wherein  $R_1$  and  $R_2$  are as defined above.


Compounds of formula VIII are novel intermediates for preparation of other Compounds of the Invention and are included per se within the present invention. Compounds of formula IX are Compounds of the Invention.

In an alternative preferred embodiment an alkoxyalkyl nitrogen protecting group, e.g. a dialkoxyalkyl nitrogen protecting group, especially a diethoxymethyl protecting group, is used in place of the trimethylsilylethoxymethyl protecting group. Such an alkoxyalkyl protecting group may be introduced by treating the corresponding 1H-imidazole of formula I, i.e. the corresponding compound of formula I in which R<sub>4</sub> is H, with a trialkyl orthoformate, e.g. triethyl orthoformate, for instance as hereinafter described in Example

The synthesis of Compounds of the Invention is further described in the following Examples.

### EXAMPLES

Example 1 and 2: 4-(4-fluorophenyl)-5-(4-pyridyl)-1-(2-(trimethylsilyl)ethoxymethyl)-imidazole and 4-(4-pyridyl)-5-(4-fluorophenyl)-1-(2-(trimethylsilyl)ethoxymethyl)imidazole




4-(4-Fluorophenyl)-5-(4-pyridyl)-1H-imidazole (3) (1g 4.18mmol) is dissolved in DMF/THF (50ml/20ml) and cooled to -78 °C. Potassium bis-(trimethylsilyl)-amide (15% in toluene; 6.7ml 5mmol) is introduced at -78 °C, stirred for 30min, then 2-(trimethylsilyl)ethoxymethylchloride is added and the reaction mixture warmed up to r.t. , poured on water after 2 hrs. and extracted 3x with ethyl acetate. The combined organic phases are dried over Na<sub>2</sub>SO<sub>4</sub>, evaporated to dryness and chromatographed (SiO<sub>2</sub> acetone/hexane 4/6 to 6/4) to give 1-(2-(trimethylsilyl)ethoxymethyl)-4-(4-

fluorophenyl)-5-(4-pyridyl)imidazole, being eluted first as white crystals (218mg 14%) followed by 4-(4-pyridyl)-5-(4-fluorophenyl)-1-(2-(trimethylsilyl)ethoxymethyl)imidazole as white crystals (590mg 38%). The correct assignment of the structures was achieved by ROESY, HSQC and HMBC spectrometry.

<sup>1</sup>H-NMR (360MHz CDCl<sub>3</sub>) of 1-(2-(trimethylsilyl)ethoxymethyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole (Example 1): 0.00 (s, 9H); 0.92 (t, 2H); 3.55 (t, 2H); 5.15 (s, 2H); 6.95 (t, 2H); 7.36 (d, 2H); 7.42 (dd, 2H); 7.72 (s, 1H); 8.68 (d, 2H) 4-(4-pyridyl)-5-(4-fluorophenyl)-1-(2-(trimethylsilyl)ethoxymethyl)imidazole (Example 2): 0.00 (s, 9H); 0.90 (t, 2H); 3.48 (t, 2H); 5.10 (s, 2H); 7.20 (t, 2H); 7.35-7.45 (m, 4H); 7.75 (s, 1H); 8.45 (d, 2H).


Alternatively, the 1H-imidazole starting material may be converted to the corresponding 4-(4-fluorophenyl)-5-(4-pyridyl)-1-(1,1-diethoxymethyl)-imidazole and 4-(4-pyridyl)-5-(4-fluorophenyl)-1-(1,1-diethoxymethyl)imidazole products.

**1-(1,1-Diethoxymethyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)imidazole and 1-(1,1-diethoxymethyl)-5-(4-fluorophenyl)-4-(4-pyridinyl)imidazole**



4-(4-fluorophenyl)-5-(4-pyridinyl)-imidazole (72.7 g; 0.304 mol) and pTsOH.H<sub>2</sub>O (1.1 g; 5 mmol) are dissolved in hot triethyl orthoformate (770 ml) and refluxed, while slowly distilling off ca. 300 ml of triethyl orthoformate and ethanol. After 2 h the reaction mixture is evaporated to dryness and taken up in tert.butyl methyl ether (500 ml). Hexane (5 l) is slowly added, the precipitate filtered off and washed with tert.butyl methyl ether/hexane (1:9). The filtrate is washed with 1N Na<sub>2</sub>CO<sub>3</sub>, dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. Xylene is added twice and evaporated again yielding the title compounds as a yellow-brownish viscous oil (79.3g; 76%; ~1:1 mixture), which is used without further purification.


**Example 3: 4-(4-fluorophenyl)-2-((RS)-1-hydroxy-4'-fluorobenzyl)-5-(4-pyridyl)imidazole**



1.6M n-BuLi in hexane (0.085ml 0.13mmol) is added at -40 °C to a solution of 1-(2-(trimethylsilyl)ethoxymethyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole (Example 2; 50mg 0.13mmol) in THF (1.4ml). After 15min at -40 °C, 4-fluorobenzaldehyde (0.018ml 0.18mmol) in THF (0.4ml) is added to the reaction mixture, which is warmed to r.t. and after 10min. poured on water and extracted 3x with ethyl acetate. The combined organic phases are dried over Na<sub>2</sub>SO<sub>4</sub>, evaporated to dryness and render the desired N-protected title compound (64mg). In order to remove the SEM protecting group, the latter material is dissolved in THF (2ml), treated with Bu<sub>4</sub>NF (4.3ml; 1M in THF) for 1h at 60 °C, poured on a saturated solution of NaHCO<sub>3</sub> and extracted 3x with ethyl acetate. The combined organic phases are dried over Na<sub>2</sub>SO<sub>4</sub>, evaporated to dryness and chromatographed (SiO<sub>2</sub> toluene/EtOH/NH<sub>3</sub>conc. 90/10/0.6) to yield the title compound as white crystals (32mg 67% over 2 steps)

<sup>1</sup>H-NMR (360 MHz DMSO-d<sub>6</sub>): 5.80 (s, 1H); 6.30 (bs, OH); 7.15 (t, 2H); 7.20-7.30 (bs, 1H); 7.37 (d, 2H); 7.42-7.48 (m, 2H); 7.52-7.58 (m, 2H); 8.38-8.51 (bs, 2H); 12.50-12.60 (bs, NH)

In an alternative procedure a mixture of 1-(1,1-diethoxymethyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)imidazole and 3-(1,1-diethoxymethyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)imidazole, prepared as described above may be used in place of 1-(2-(trimethylsilyl)ethoxymethyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole; for example as described below for the preparation of 4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(2,3,5,6-tetrafluoropyridinyl)imidazole.

**4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(2,3,5,6-tetrafluoropyridinyl)imidazole**

1.6 M nBuLi (66 ml; 45 mmol) is added at  $-45^{\circ}\text{C}$  to a ~1:1 mixture of 1-(1,1-diethoxymethyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)imidazole and 1-(1,1-diethoxymethyl)-5-(4-fluorophenyl)-4-(4-pyridinyl)imidazole (15 g; 43 mmol) in THF (210 ml). After 15 min. at  $-45^{\circ}\text{C}$  the reaction mixture is cooled to  $-55^{\circ}\text{C}$  and pentafluoropyridine (5.1 ml; 47 mmol) is rapidly introduced. The cooling bath is removed, the reaction mixture allowed to warm to  $-15^{\circ}\text{C}$  and poured on water (1 l), which is then acidified with 2N HCl (100 ml). After stirring for 5 min. the mixture is combined with a saturated solution of  $\text{Na}_2\text{CO}_3$  and extracted with ethyl acetate three times. The combined organic phases are dried over  $\text{Na}_2\text{SO}_4$ , filtered and evaporated to dryness rendering the title compound as brownish crystals (16.3 g). Chromatography ( $\text{SiO}_2$ ; acetone/hexanes 1:1) yields the title compound together with some unreacted and unprotected imidazole starting material, which could be removed by washing with acetone yielding the title compound (8.7 g; 52.4%).

$^1\text{H-NMR}$  (360 Mhz  $\text{CDCl}_3$ ): 7.30-7.40 (bt, 2H); 7.45 (d, 2H); 7.58 (bq; 2H); 8.52 (bs, 2H).

MS (m/z): 388.9 (MH $^{+}$ )

Using substantially similar procedures to those described in Example 3 and appropriate starting materials the following compounds of formula X are prepared as set out in Table I.













Table 1

Example No.	X''	D'	NMR data etc.
4	-SO <sub>2</sub> -		<sup>1</sup> H-NMR (360 MHz DMSO-d <sub>6</sub> ): 7.28 (t, 2H); 7.35 (d, 2H); 7.49 (m, 2H); 7.67-7.80 (m, 3H); 8.05 (d, 2H); 8.50 (d, 2H)
5	-S-		<sup>1</sup> H-NMR (360 MHz DMSO-d <sub>6</sub> ): 7.20-7.45 (m, 9H); 7.55 (dd, 2H); 8.40-8.60 (m, 2H)
6	-Se-		<sup>1</sup> H-NMR (360 MHz DMSO-d <sub>6</sub> ): 7.25-7.36 (5H); 7.40 (d, 2H); 7.48-7.55 (m, 4H); 8.48 (d, 2H)
7	direct bond		<sup>1</sup> H-NMR (360 MHz DMSO-d <sub>6</sub> ), 7/3 mixture of NH-tautomers: 1.20-1.40 (bs, 1H); 1.51 (bs, 3H); 1.60-1.72 (m, 2H); 1.72-1.85 (m, 2H); 1.90-2.05 (M, 2H); 5.60 (s, 0.7H); 5.67 (s, 0.3H); 7.12-7.21 (bt, 0.3H); 7.30 (bt, 0.7H); 7.40 (d, 2H); 7.48 (bt, 2H); 8.40 (bd, 1.4H); 8.48 (bd, 0.6H); 12.26 (s, 1H)
8	direct bond		<sup>1</sup> H-NMR (360 Mhz DMSO-d <sub>6</sub> ): 0.00 (bs, 1H); 0.20-0.30 (m, 2H); 0.32-0.43 (m, 2H); 0.50-0.60 (m, 1H); 0.65-0.75 (m, 1H); 1.05-1.15 (m, 1H); 1.60-1.70 (m, 1H); 1.81-1.91 (m, 1H); 2.10-2.20 (m, 1H); 7.15-7.40 (m, 4H); 7.50 (dd, 2H); 8.40 (bs, 1H); 8.45 (bs, 1H); 12.20 (bs, 1H) MS (m/z): 348 (MH <sup>+</sup> )
9	-CH <sub>2</sub> -		<sup>1</sup> H-NMR (360 Mhz CDCl <sub>3</sub> ): 0.48 (q, 2H); 0.68 (q, 2H); 1.20 (m, 1H); 2.84 (d, 2H); 7.10 (t, 2H); 7.45 (dd, 2H); 7.55 (d, 2H); 8.45 (d, 2H) MS(m/z):294(MH <sup>+</sup> )



Example No.	X''	D'	NMR data etc.
10	direct bond		1H-NMR (360 Mhz CDCl3): 7.30-7.40 (bt, 2H); 7.45 (d, 2H); 7.58 (bq; 2H); 8.52 (bs, 2H). MS (m/z): 388.9 (MH+)
11	direct bond		1H-NMR (360 Mhz DMSO): 1.83 (bd; 2H); 1.90 (bs, 2H); 2.13 (bd, 2H); 2.25 (bs, 2H); 2.40 (bd, 2H); 3.12 (bs, 3H); 5.15 (bs, 1H); 7.20-7.30 (bs, 2H); 7.46 (d, 2H); 7.45 (dd, 2H); 8.35-8.50 (s, 2H); 12.25 (s, 1H). MS (m/z): 377.1 (MH-)
12	direct bond		1H-NMR (360 Mhz DMSO, 120 C): 2.18 (bt; 1H); 2.21 (bt; 1H); 2.40-2.50 (m, 2H); 2.78 (s, 3H); 2.7-2.95 (bm, 4H); 5.45 (bs, 1H); 7.21 (dd, 2H); 7.42 (dd, 2H); 7.51 (dd, 2H); 8.45 (dd, 2H). MS (m/z): 352 (M+)

**Example 13: 2-(1-Cyclohexenyl)-4-(4-fluorophenyl)- 5-(4-pyridyl)imidazole**



The product of Example 7, 2-((1-hydroxy)cyclohexyl)-4-(4-fluorophenyl)- 5-(4-pyridyl)-1H-imidazole (50mg 0.15mmol) is dissolved in toluene (100ml) and refluxed with pTsOH (100mg) for 15min. The reaction mixture is poured on saturated NaHCO<sub>3</sub> and extracted 3x with ethyl acetate. The combined organic phases are dried over

Na<sub>2</sub>SO<sub>4</sub>, evaporated to dryness and chromatographed (SiO<sub>2</sub> acetone/hexane 4/6) to render the title compound as white crystals (38mg 81%)

<sup>1</sup>H-NMR (360 MHz DMSO-d<sub>6</sub>), 8/2 mixture of NH-tautomers: 1.60 (m, 2H); 1.68 (m, 2H); 2.18 (bs, 2H); 2.50 (bs, 2H); 6.55 (bs, 0.8H); 6.62 (bs, 0.2H); 7.15-7.60 (m, 6H); 8.40 (d, 1.6H); 8.52 (d, 0.4H); 12.25 (bs, 0.2H); 12.37 (bs, 0.8H)

Using substantially similar procedures to those described in Example 13 and appropriate starting materials the following compounds of formula X are prepared as set out in Table 2





Table 2

Example No.	X''	D'	NMR data etc.
14	direct bond		<sup>1</sup> H-NMR (360 Mhz DMSO, 120 C): 1.55-1.65 (m, 2H); 1.72 (dt, 2H); 2.00-2.18 (m, 2H); 2.22 (d, 1H); 2.35 (s, 3H); 3.35 (bt, 1H); 3.42 (bt, 1H); 6.68 (bs, 1H); 7.10-7.30 (bd, 2H); 7.40 (d, 2H); 7.50 (dd, 2H); 8.35-8.55 (bd, 2H); 12.00 (bs, 1H). MS (m/z): 361.1 (M+H+).
15 <sub>1</sub>	direct bond		<sup>1</sup> H-NMR (360 MHz, DMSO, 120 C): 2.35 (s, 3H); 2.65 (s, 4H); 3.10 (s, 2H); 6.55 (bs, 1H); 7.10-7.30 (bd, 2H); 7.42 (bs, 2H); 7.52 (bt, 2H); 8.35-8.55 (bd, 2H); 11.90-12.10 (bs, 1H). MS (m/z): 334 (M+).

1 - SOCl<sub>2</sub> in pyridine is used in place of pTsoH in toluene

**Example 16 and 17: 4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(2-amino-3,5,6-trifluoropyridinyl)imidazole and 4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(2,6-diamino-3,5,-difluoropyridinyl)imidazole**



The product of Example 10, 4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(2,3,5,6-tetrafluoropyridinyl)imidazole (2g; 5.15mmol) is suspended in  $\text{NH}_3$  conc. (25%; 200ml) and heated to  $150^\circ\text{C}$  in a sealed steel cylinder for 5h. Water is evaporated and the residue chromatographed ( $\text{SiO}_2$ , TBME/MeOH/ $\text{NH}_3$  conc 98/2/0.2) to yield the title compounds 4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(2-amino-3,5,6-trifluoropyridinyl)imidazole (880mg; 44.4%) and 4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(2,6-diamino-3,5-difluoropyridinyl)imidazole (650mg; 33%) as slightly colored crystals.

4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(2-amino-3,5,6-trifluoropyridinyl)imidazole

$^1\text{H-NMR}$  (400MHz,  $\text{DMSO-d}_6$ ) mixture of tautomers: 6.80 (s, 2H); 7.25 (bt, 0.6H); 7.38 (t, 1.4H); 7.45 (d, 2H); 7.58 (t, 2H); 8.49 (d, 1.4H); 8.62 (bd, 0.6H)

MS (m/z): 385 (M $^+$ )


4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(2,6-diamino-3,5,-difluoropyridinyl)imidazole:

$^1\text{H-NMR}$  (400MHz,  $\text{DMSO-d}_6$ ) mixture of tautomers: 5.75 (s, 2H); 7.22 (t, 0.6H); 7.33 (t, 1.4H); 7.41-7.47 (m, 2H); 7.52-7.58 (m, 2H); 8.47 (d, 1.4H); 8.58 (d, 0.6H)

MS (m/z): 382 (M $^+$ )


**Example 18: 4-(4-Fluorophenyl)-2-((1-amino)cyclohexyl)-5-(4-pyridyl)imidazole**

**a) 1-(4-Fluorophenyl)-2-bromo-2-(4-pyridyl)ethanone hydrobromide**



Bromine (74.4g; 0.46mol) in acetic acid (160ml) is added within 10min to a solution of 4-fluorophenyl 4-pyridylmethylketone (I.Lantos et al. J.Med.Chem. 1984, 27, 72-75) (100g; 0.46mol) in acetic acid (800ml) at 21°C. The yellow crystals are filtered off, washed with acetic acid, ether and hexane and then dried under reduced pressure to provide the hydrobromide of the desired compound (250g; 72%).

**b) 4-(4-Fluorophenyl)-2-(1-N-carbobenzoyloxycyclohexyl)-5-(4-pyridyl)imidazole**




1-N-carbobenzoyloxy-1-cyclohexanecarboxylic acid (E.Didier et al. Tetrahedron 1992, 48(39), 8471) (13.9g; 50mmol), and ammoniumcarbonate (Fluka; 4.8g; 50mmol) are dissolved in DMF (50ml) and heated to 110°C for 10min. until gas evolution ceases. The reaction flask is cooled to 60°C, 1-(4-fluorophenyl)-2-bromo-2-(4-pyridyl)ethanone hydrobromide (3.75g; 10mmol) added as a solid and heated to 125°C for 2.5h. The reaction mixture is poured on 1M Na<sub>2</sub>CO<sub>3</sub> and extracted with ethyl acetate three times. The combined organic phases are washed with water, dried over Na<sub>2</sub>SO<sub>4</sub>, evaporated to dryness and yielded the crude title compound, (4.8g) which after chromatography (SiO<sub>2</sub>; ethyl acetate) gives the pure title compound as light yellow crystals (1.4g; 30%).

<sup>1</sup>H-NMR (400MHz; CDCl<sub>3</sub>): 1.25-2.40 (m, 10H); 5.12 (s, 2H); 7.08-7.16 (m, 2H); 7.30-7.50 (m, 9H); 8.50 (d, 2H)

MS (m/z): 471.2 (MH<sup>+</sup>)

**c) 4-(4-Fluorophenyl)-2-(1-aminocyclohexyl)-5-(4-pyridyl)imidazole (243-653)**




4-(4-Fluorophenyl)-2-((1-N-carbobenzyloxy)cyclohexyl)-5-(4-pyridyl)imidazole (1.6g; 4mmol) is dissolved in EtOH (140ml) and hydrogenated at 1 atm in the presence of Pd/C (10%; 0.7g) for 2h at room temperature. Filtration and evaporation of the solvent followed by recrystallisation from ethyl acetate/ether yields the desired amine as off-white crystals (0.63g; 47%).

<sup>1</sup>H-NMR (400MHz; DMSO-d<sub>6</sub>): 1.25-1.78 (m, 8H); 1.95-2.10 (bt, 2H); 7.25-7.34 (bt, 2H); 7.40 (d, 2H); 7.47-7.52 (m, 2H); 8.43 (d, 2H)

MS (m/z): 336 (M<sup>+</sup>)

**Example 19: 4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(4-n-butyloxy-1-methylpiperidin-4-yl)imidazole**



The product of xample 12, 4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(4-hydroxy-1-methylpiperidin-4-yl)imidazole (22.2g; 63 mmol) is dissolved in 1-butanol (1 l) upon warming to 40<sup>0</sup> C. H<sub>2</sub>SO<sub>4</sub> conc (27.8g; 283 mmol) is added dropwise and the initially resulting suspension is refluxed for 3.5 h, while distilling off ~200ml of 1-butanol. The reaction mixture is cooled to room temperature and poured on a saturated solution of

Na<sub>2</sub>CO<sub>3</sub> (500 ml). The aqueous phase is extracted with ethyl acetate and the combined organic phases dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated to dryness. Purification by chromatography (SiO<sub>2</sub>; TBME/MeOH/NH<sub>3</sub>conc. 96/4/0.4 to 70/30/1) yields the title compound as yellow crystals (15.5g; 60.3%). A sample is recrystallized from CH<sub>2</sub>Cl<sub>2</sub>/TBME to render colorless crystals: m.p. 177° C.

<sup>1</sup>H-NMR (400MHz; DMSO-d<sub>6</sub>): mixture of tautomers, which duplicates aromatic signals. 0.80 (bt, 3H); 1.25-1.35 (m, 2H); 1.38-1.48 (m, 2H); 2.12 (bs, 4H); 2.18 (s, 3H); 2.35 (m, 2H); 2.42 (m, 2H); 3.12 (t, 2H); 7.18 (t, 0.5H); 7.32 (t, 1.5H); 7.40 (m, 2H); 7.48 (m, 2H); 8.40 (d, 1.5H); 8.53 (d, 0.5H).  
MS (m/z): 408 (M+, 20%); 351 (100%); 335 (95%).

Compounds of the Invention, in free or pharmaceutically acceptable acid addition salt or physiologically cleavable ester form, which exhibit pharmacological activity and are useful as pharmaceuticals, e.g. for therapy, in the treatment of diseases and conditions as hereinafter set forth, are hereinafter referred to as Agents of the Invention.

In particular Agents of the Invention possess p38 MAP kinase (Mitogen Activated Protein Kinase) inhibiting activity. Thus the Agents of the Invention act to inhibit production of inflammatory cytokines, such as TNF- $\alpha$  and IL-1, and also to potentially block the effects of these cytokines on their target cells. These and other pharmacological activities of the Agents of the Invention as may be demonstrated in standard test methods for example as described below:

#### p38 MAP kinase Assay

The substrate (GST-ATF-2; a fusion protein comprising amino acids 1-109 of ATF-2 and the GST protein obtained by expression in *E. coli*) is coated onto the wells of microtiter plates (50  $\mu$ l/well; 1  $\mu$ g/ml in PBS/0.02% Na azide) overnight at 4 °C. The following day, the microtiter plates are washed four times with PBS/0.5% Tween 20/0.02% Na azide and are blocked with PBS/2% BSA/0.02% Na Azide for 1 h at 37 °C. Plates are washed again 4 times with PBS/0.5% Tween 20/0.02% Na azide. The

kinase cascade reaction is then started by adding the following reactants in 10  $\mu$ l aliquots to a final reaction volume of 50  $\mu$ l.

1. Agents of the Invention titrated from 10 to 0.001  $\mu$ M in 10-fold dilutions or solvent (DMSO) or H<sub>2</sub>O.
2. Kinase buffer (5x); pH 7.4; 125 mM Hepes (Stock at 1M; Gibco #15630-056), 125 mM  $\beta$ -glycerophosphate (Sigma #G-6251):125 mM MgCl<sub>2</sub> (Merck #5833); 0.5 mM Sodium orthovanadate (Sigma #5-6508), 10 mM DTT (Boehringer Mannheim #708992). The (5x) kinase buffer must be prepared fresh the day of the assay from 5x stock solutions kept at RT. DTT is kept at -20 °C and is added as the last reagent.
3. His-p38 MAP kinase (10 ng/well; Novartis - a fusion protein comprising full length murine p38 MAP kinase and a His tag, obtained by expression in E. coli)
4. cold ATP (final concentration 120  $\mu$ M; Sigma #A-9187)
5. Water

After 1h at 37 °C the kinase reaction is terminated by washing the plates four times as previously described. Phosphorylated GST-ATF-2 is then detected by adding:

1. the PhosphoPlus ATF-2 (Thr71) Antibody (50  $\mu$ l/well; 1/1000 final dilution in PBS/2% BSA/0.02% Na Azide; New England Biolabs #9221L) for 90 min at RT.
2. Biotin labelled goat-anti-rabbit IgG (50  $\mu$ l/well; 1/3000 final dilution in PBS/2% BSA/0.02% Na Azide; Sigma #B-9642) for 90 min at RT.
3. Streptavidin-alkaline phosphatase (50  $\mu$ l/well; 1/5000 dilution in PBS/2% BSA/0.02% Na Azide; Jackson ImmunoResearch #016-050-084 ) for 30 min at RT.
4. Substrate (100  $\mu$ l/well; Sigma 104 Phosphatase substrate tablets, 5 mg/tablet; #104-105; 1 mg/ml in substrate buffer, Diethanolamine (97 ml/l; Merck #803116) + MgCl<sub>2</sub>.6H<sub>2</sub>O (100 mg/l; Merck #5833) + Na Azide (0.2 g/l) + HCl 1M to pH 9.8) 30 min at RT.

After step 1,2 and 3 the microtiter plates are washed four times with PBS/0.5% Tween 20/0.02% Na azide. After step 4, the plates are read in a Bio-Rad microplate reader in a dual wavelength mode (measurement filter 405 nm and reference filter 490 nm). The background value (without ATP) is subtracted and IC<sub>50</sub> values are calculated using the Origin computer program (4 parameter logistic function).

Agents of the Invention typically have  $IC_{50}$ s for p38 MAP kinase inhibition in the range from about 1  $\mu$ M to about 10 nM or less when tested in the above assay. For example, the compound of Example 17 has an  $IC_{50}$  of about 10 nM in this assay.

#### Assay for Inhibition of TNF- $\alpha$ release from hPBMCs

Human peripheral blood mononuclear cells (hPBMCs) are prepared from the peripheral blood of healthy volunteers using ficoll-hypaque density separation according to the method of Hansell et al., J. Imm. Methods (1991) 145: 105. and used at a concentration of  $10^5$  cells/well in RPMI 1640 plus 10% FCS. Cells are incubated with serial dilutions of the test compounds for 30 minutes at 37°C prior to the addition of IFNg (100 U/ml) and LPS (5 mg/ ml) and subsequently further incubated for three hours. Incubation is terminated by centrifugation at 1400 RPM for 10 min. TNF- $\alpha$  in the supernatant is measured using a commercial ELISA (Innotest hTNFa, available from Innogenetics N.V., Zwijnaarde, Belgium). Agents of the Invention are tested at concentrations of from 0 to 10 mM. Exemplified Agents of the Invention typically suppress TNF release in this assay with an  $IC_{50}$  of from about 1  $\mu$ M to about 10 nM or less when tested in this assay. For example, the compound of Example 17 has an  $IC_{50}$  of about 90 nM when tested in this assay.

#### Assay for Inhibition of TNF- $\alpha$ Production in LPS stimulated mice

Injection of lipopolysaccharide (LPS) induces a rapid release of soluble tumour necrosis factor (TNF- $\alpha$ ) into the periphery. This model is be used to analyse prospective blockers of TNF release in vivo.

LPS (20 mg/kg) is injected i.v. into OF1 mice (female, 8 week old). One (1) hour later blood is withdrawn from the animals and TNF levels are analysed in the plasma by an ELISA method using an antibody to TNF- $\alpha$ . Using 20 mg/kg of LPS levels of up to 15 ng of TNF- $\alpha$  / ml plasma are usually induced. Compounds to be evaluated are given either orally or s.c. 1 to 4 hours prior to the LPS injection. Inhibition of LPS-induced TNF-release is taken as the readout.



Agents of the Invention typically inhibit TNF production to the extent of from about 50% up to about 90% or more in the above assay when administered at 10 mg/kg p.o.. For example the compound of Example 17 inhibits TNF production to the extent of about 80% in this assay.

As indicated in the above assays Agents of the Invention are potent inhibitors of TNF- $\alpha$  release. Accordingly, the Novel Compounds have pharmaceutical utility as follows:

Agents of the Invention are useful for the prophylaxis and treatment of diseases or pathological conditions mediated by cytokines such as TNF $\alpha$  and IL-1, e.g., inflammatory conditions, autoimmune diseases, severe infections, and organ or tissue transplant rejection, e.g. for the treatment of recipients of heart, lung, combined heart-lung, liver, kidney, pancreatic, skin or corneal transplants and for the prevention of graft-versus-host disease, such as following bone marrow transplants.

Agents of the Invention are particularly useful for the treatment, prevention, or amelioration of autoimmune disease and of inflammatory conditions, in particular inflammatory conditions with an aetiology including an autoimmune component such as arthritis (for example rheumatoid arthritis, arthritis chronica progrediente and arthritis deformans) and rheumatic diseases. Specific auto-immune diseases for which Agents of the Invention may be employed include autoimmune haematological disorders (including e.g. hemolytic anaemia, aplastic anaemia, pure red cell anaemia and idiopathic thrombocytopenia), systemic lupus erythematosus, polychondritis, sclerodoma, Wegener granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, psoriasis, Steven-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (including e.g. ulcerative colitis and Crohn's disease), endocrine ophthalmopathy, Graves disease, sarcoidosis, multiple sclerosis, primary biliary cirrhosis, juvenile diabetes (diabetes mellitus type I), uveitis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthritis and glomerulonephritis (with and without nephrotic

syndrome, e.g. including idiopathic nephrotic syndrome or minimal change nephropathy).

Agents of the Invention are also useful for the treatment, prevention, or amelioration of asthma, bronchitis, pneumoconiosis, pulmonary emphysema, and other obstructive or inflammatory diseases of the airways.

Agents of the Invention are useful for treating undesirable acute and hyperacute inflammatory reactions which are mediated by TNF, especially by TNF $\alpha$ , e.g., acute infections, for example septic shock (e.g., endotoxic shock and adult respiratory distress syndrome), meningitis, pneumonia; and severe burns; and for the treatment of cachexia or wasting syndrome associated with morbid TNF release, consequent to infection, cancer, or organ dysfunction, especially AIDS -related cachexia, e.g., associated with or consequential to HIV infection.

Agents of the Invention are particularly useful for treating diseases of bone metabolism including osteoarthritis, osteoporosis and other inflammatory arthritides.

For the above indications the appropriate dosage will, of course, vary depending, for example, on the particular Agent of the Invention employed, the subject to be treated, the mode of administration and the nature and severity of the condition being treated. However, in general, satisfactory results in animals are obtained at daily dosages of from about 1 to about 10mg/kg/day p.o.. In larger mammals, for example humans, an indicated daily dosage is in the range of from about 50 to about 750mg of Agent of the Invention administered orally once or, more suitably, in divided dosages two to four times/day.

The Agents of the Invention may be administered by any conventional route, e.g. orally, for example in the form of solutions for drinking, tablets or capsules or parenterally, for example in the form of injectable solutions or suspensions. Normally for systemic administration oral dosage forms are preferred, although for some indications the Agents of the Invention may also be administered topically or dermally, e.g. in the form of a dermal cream or gel or like preparation or, for the purposes of


application to the eye, in the form of an ocular cream, gel or eye-drop preparation; or may be administered by inhalation, e.g., for treating asthma. Suitable unit dosage forms for oral administration comprise e.g. from 25 to 250mg Novel Compound per unit dosage.

In accordance with the foregoing the present invention also provides in a further series of embodiments:

- A. A method of inhibiting production of soluble TNF, especially  $\text{TNF}\alpha$ , or of reducing inflammation in a subject (i.e., a mammal, especially a human) in need of such treatment which method comprises administering to said subject an effective amount of an Agent of the Invention, or a method of treating any of the above mentioned conditions, particularly a method of treating an inflammatory or autoimmune disease or condition, e.g. rheumatoid arthritis, or alleviating one or more symptoms of any of the above mentioned conditions.
- B. An Agent of the Invention for use as a pharmaceutical, e.g. for use as an immunosuppressant or antiinflammatory agent or for use in the prevention, amelioration or treatment of any disease or condition as described above, e.g., an autoimmune or inflammatory disease or condition.
- C. A pharmaceutical composition comprising an Agent of the Invention in association with a pharmaceutically acceptable diluent or carrier, e.g., for use as an immunosuppressant or anti-inflammatory agent or for use in the prevention, amelioration or treatment of any disease or condition as described above, e.g., an autoimmune or inflammatory disease or condition.
- D. Use of an Agent of the Invention in the manufacture of a medicament for use as an immunosuppressant or anti-inflammatory agent or for use in the prevention, amelioration or treatment of any disease or condition as described above, e.g., an autoimmune or inflammatory disease or condition.

CLAIMS

1. A 2-substituted 4,5-diaryl imidazole in which:
  - i) the nitrogen atom at the 1 position is substituted by a trialkylsilyl-containing substituent, or
  - ii) the substituent at the 2 position is arylalkyl, arylsulfonyl, arylthio arylseleno, aryltelluro, cycloalkyl, cycloalkenyl, alkylcycloalkyl, alkylcycloalkenyl, amino or hydrazino, or mono- or bicyclic N-heterocyclyl in which the N containing ring has six ring members, provided that the substituent at the 2 position is not piperidin-4-yl, 1-carboxylic-acid-tert-butyl-ester-4-benzyl-piperidin-4-yl, 1,4-dimethyl-piperidin-4-yl, 4-benzyl-piperidin-4-yl, or piperidin-4-yl which is further substituted only at the N atom,
 in free or pharmaceutically-acceptable acid addition salt or physiologically-cleavable ester form.
  
2. A compound of formula I



wherein

R<sub>1</sub> is 4-pyridyl, pyrimidinyl, quinazolin-4-yl, quinolyl, isoquinolyl, 1-imidazolyl or 1-benzamidazolyl, which is optionally substituted with one or two substituents each of which is independently selected from

C<sub>1-4</sub>alkyl, halogen, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkylthio, NR<sub>5</sub>R<sub>6</sub>, or an N-heterocyclyl ring having 5 to 7 ring atoms and optionally containing an additional heteroatom selected from O, S, or N

wherein R<sub>5</sub> and R<sub>6</sub> is each independently C<sub>1-4</sub>alkyl;

R<sub>2</sub> is phenyl, naphth-1-yl or naphth-2-yl which is optionally substituted by up to 5 substituents;

$R_3$  is hydrogen,  
 heterocyclyl,  
 heterocyclyl $C_{1-10}$ alkyl,  
 tri $C_{1-4}$ alkylsilyl $C_{1-10}$ alkoxy $C_{1-4}$ alkyl,  
 optionally halo substituted  $C_{1-10}$ alkyl,  $C_{2-10}$  alkenyl,  $C_{2-10}$  alkynyl,  $C_{3-7}$  cycloalkyl,  $C_{3-7}$  cycloalkyl $C_{1-10}$ alkyl,  $C_{5-7}$  cycloalkenyl, aryl, aryl $C_{1-10}$ alkyl, heteroaryl, or heteroaryl $C_{1-10}$ alkyl,  
 optionally mono-or di- $C_{1-4}$ alkyl-substituted $C_{0-10}$ alkyl-oxycarbonyl or -oxythiocarbonyl optionally substituted by  $C_{1-10}$ alkyl,  $C_{3-7}$  cycloalkyl, heterocyclyl, heterocyclyl $C_{1-10}$ alkyl, aryl, aryl $C_{1-10}$ alkyl, heteroaryl, heteroaryl $C_{1-10}$ alkyl, or  
 optionally mono-or di- $C_{1-4}$ alkyl-substituted $C_{1-10}$ alkyl  
 -cyano,  
 -nitro,  
 -hydroxy, - $C_{1-10}$ alkoxy, - $C_{3-7}$ cycloalkoxy, -heterocycloxy, -heterocyclyl $C_{1-10}$ alkoxy, -aryloxy, -aryl $C_{1-10}$ alkoxy, -heteroaryloxy, -heteroaryl $C_{1-10}$ alkoxy (and thio oxy analogues thereof),  
 optionally substituted amino, carboxylate, thiocarboxylate, carbonyl or thiocarbonyl, sulphinyl or sulphonyl;

$R_4$  is  $C_{0-4}$ alkyl mono-or di- $C_{3-7}$ cycloalkyl optionally substituted by -halo, -OH, - $C_{1-4}$  alkyl, - $C_{1-4}$  alkoxy, - $C_{1-4}$  thioalkoxy, -nitro, -amino, - $C_{1-4}$  alkylsulphinyl, - $C_{1-4}$  alkylsulphonyl, -carboxylate or -ester,  
 - $NH_2$ ,  $NR_7R_8$ ,  $NHNHR_9$ ,  
 wherein independently each  $R_7$ ,  $R_8$  or  $R_9$  is  $C_{1-4}$ alkyl,  $C_{2-4}$ alkenyl,  $C_{2-6}$ alkynyl,  
 -X-  $C_{5-10}$  aryl (including heteroaryl)  
 wherein X is S,  $SO_2$ , Se, Te or  $C_{1-4}$ alkyl,  
 mono-or bicyclic N-heterocyclyl in which the N containing ring has six ring members,  
 or aryl or heteroaryl optionally substituted by up to 4 substituents,  
 provided that

when  $R_3$  is not tri $C_{1-4}$ alkylsilyl $C_{1-10}$ alkoxy $C_{1-4}$ alkyl,


$R_4$  is not aryl or heteroaryl optionally substituted by up to 4 substituents, except when  $R_4$  is mono- or bicyclic N-heterocyclyl in which the N containing ring has six ring members, and

provided that

$R_4$  is not piperidin-4-yl, 1-carboxylic-acid-tert-butyl-ester-4-benzyl-piperidin-4-yl, 1,4-dimethyl-piperidin-4-yl, 4-benzyl-piperidin-4-yl, or piperidin-4-yl which is further substituted only at the N atom,

in free or pharmaceutically-acceptable acid addition salt or physiologically-cleavable ester form.


3. A compound according to claim 2 of formula I'



wherein

$R_3'$  is tri $C_{1-4}$ alkylsilyl $C_{1-10}$ alkoxy $C_{1-4}$ alkyl, and  $R_1$ ,  $R_2$  and  $R_4$  are as defined in claim 2, in free or pharmaceutically-acceptable acid addition salt or physiologically-cleavable ester form.

4. A compound according to claim 2 of formula III




III

wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $X$  are as defined in claim 2 and  $R_{11}$  represents from 1 to 5 substituents independently selected from H, halo, OH,  $C_{1-4}$  alkyl,  $C_{1-4}$

alkoxy, C<sub>1-4</sub> thioalkoxy, nitro, amino, C<sub>1-4</sub> alkylsulphinyl, C<sub>1-4</sub> alkylsulphonyl, carboxylate or ester, in free or pharmaceutically-acceptable acid addition salt or physiologically-cleavable ester form.

5. A compound according to claim 2 of formula IV



wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are as defined in claim 2, D is C<sub>3-7</sub>cycloalkyl, C<sub>3-7</sub>cycloalkenyl or a mono- or bicyclic N-heterocyclyl in which the N containing ring has 6 ring members and X' is a direct bond or -CR<sub>12</sub>R<sub>13</sub>-

wherein R<sub>12</sub> is H or C<sub>1-4</sub>alkyl and R<sub>13</sub> is H or C<sub>1-4</sub>alkyl optionally substituted by C<sub>3-7</sub>cycloalkyl or C<sub>3-7</sub>cycloalkenyl

in free or pharmaceutically-acceptable acid addition salt or physiologically-cleavable ester form.

6. 4-(4-fluorophenyl)-5-(4-pyridyl)-1-(2-trimethylsilylethoxymethyl)imidazole;  
 4-(4-pyridyl)-5-(4-fluorophenyl)-1-(2-trimethylsilylethoxymethyl)imidazole;  
 4-(4-fluorophenyl)-2-((RS)-1-hydroxy-4'-fluorobenzyl)-5-(4-pyridyl)imidazole;  
 4-(4-fluorophenyl)-2-(phenylsulfonyl)-5-(4-pyridyl)imidazole;  
 4-(4-fluorophenyl)-2-(phenylthio)-5-(4-pyridyl)imidazole;  
 4-(4-fluorophenyl)-2-(phenylseleno)-5-(4-pyridyl)imidazole;  
 4-(4-fluorophenyl)-2-((1-hydroxy)cyclohexyl)-5-(4-pyridyl)imidazole;  
 2-(1-Cyclohexenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole;  
 2-(1,2-Dicyclopropylethyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole;  
 2-(Cyclopropylmethyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole;  
 4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(2,3,5,6-tetrafluoropyridinyl)imidazole;  
 4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(tropan-3 $\alpha$ -ol-3 $\beta$ -yl)imidazole;  
 4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(4-hydroxy-1-methylpiperidin-4-yl)imidazole;

+/- 4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(8-methyl-8-azabicyclo[3.2.1]oct-2-en-3-yl)imidazole

4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(2-amino-3,5,6-trifluoropyridinyl)imidazole;

4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(2,6-diamino-3,5-difluoropyridinyl)imidazole;


4-(4-fluorophenyl)-2-((1-amino)cyclohexyl)-5-(4-pyridyl)imidazole;

4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(4-n-butyloxy-1-methylpiperidin-4-yl)imidazole, or

4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(1-methyl-4-piperidenyl)imidazole,

in free or pharmaceutically-acceptable acid addition salt or physiologically-cleavable ester form.

7. A process for the preparation of a compound of formulae III as defined in claim 5 or of a compound of formula IV as defined in claim 6 comprising reacting a compound of formula VIII



wherein  $R_1$  and  $R_2$  are as defined above,

with the corresponding aldehyde, ketone, disulfonylamine, disulfide, diselenide, ditelluride or halide and, if required introducing the desired  $R_3$  substituent or further transforming the product obtained and optionally recovering the compound in free or salt form.

8. A method of inhibiting production of soluble TNF or of reducing inflammation in a subject in need of such treatment which method comprises administering to said subject an effective amount of a compound as defined in claim 1 or 2.



9. A compound as defined in claim 1 or 2 for use as a pharmaceutical, e.g. for use as an immunosuppressant or antiinflammatory agent.
10. A pharmaceutical composition comprising a compound as defined in claim 1 or 2 in association with a pharmaceutically acceptable diluent or carrier, e.g., for use as an immunosuppressant or anti-inflammatory agent.
11. Use of a compound as defined in claim 1 or 2 in the manufacture of a medicament for use as an immunosuppressant or anti-inflammatory agent.

# INTERNATIONAL SEARCH REPORT

Int .tional Application No

PCT/EP 98/03930

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D401/04 C07F7/08 A61K31/44 A61K31/695 C07D401/14  
C07D451/02 C07D403/04 A61K31/445

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D C07F A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97 12876 A (MERCK & CO INC ) 10 April 1997 cited in the application see claims ---	1-5,8-11
Y	WO 95 03297 A (SMITHKLINE BEECHAM CORPORATION) 2 February 1995 cited in the application see claims ---	1-5,8-11
Y	WO 93 14081 A (SMITHKLINE BEECHAM CORPORATION) 22 July 1993 see claims ---	1-5,8-11
Y	WO 93 14082 A (SMITHKLINE BEECHAM CORP) 22 July 1993 see page 3, line 35 - page 4, line 10; claims ---	1-5,8-11
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

21 October 1998

Date of mailing of the international search report

28/10/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Henry, J

# INTERNATIONAL SEARCH REPORT

Int .tional Application No

PCT/EP 98/03930

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO 96 03387 A (G.D.SEARLE &amp; CO )</p> <p>8 February 1996</p> <p>see claims</p> <p>-----</p>	1-5,8-11

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 98/ 03930

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 8  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim 8  
is directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/03930

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9712876 A	10-04-1997	AU 7514396 A	28-04-1997
		CZ 9801043 A	15-07-1998
		EP 0854870 A	29-07-1998
		NO 981528 A	05-06-1998
		PL 326025 A	17-08-1998
WO 9503297 A	02-02-1995	AU 7629594 A	20-02-1995
		ZA 9405363 A	14-03-1995
WO 9314081 A	22-07-1993	AU 3592393 A	03-08-1993
		BG 98902 A	30-06-1995
		BR 9305809 A	18-02-1997
		CA 2127876 A	22-07-1993
		CN 1083473 A	09-03-1994
		CZ 9401688 A	18-01-1995
		EP 0623126 A	09-11-1994
		ES 2053401 A	16-07-1994
		FI 943319 A	12-09-1994
		HU 69714 A	28-09-1995
		JP 7503017 T	30-03-1995
		MX 9300141 A	29-07-1994
		NO 942618 A	30-08-1994
		NZ 249301 A	25-06-1996
		OA 9963 A	11-12-1995
		SK 83594 A	08-03-1995
		US 5686455 A	11-11-1997
		ZA 9300213 A	18-11-1993
WO 9314082 A	22-07-1993	AU 3592493 A	03-08-1993
		EP 0624159 A	17-11-1994
		JP 7503018 T	30-03-1995
WO 9603387 A	08-02-1996	US 5620999 A	15-04-1997
		AU 3271695 A	22-02-1996
		CA 2195846 A	08-02-1996
		EP 0772601 A	14-05-1997